This document references the following Lymphoma Research Foundation (LRF) Grant Programs:

- Adolescent/Young Adult Lymphoma Correlative Studies Grant
- Mantle Cell Lymphoma Therapeutic Studies Grant

For questions about the Young Investigator Grant Programs, please see the separate Frequently Asked Questions (FAQ) document pertaining to those programs.

For technical assistance with the application submission portal, please contact the proposalCENTRAL helpline. The proposalCENTRAL helpline is available for questions from applicants during normal business hours (8:30AM– 5:00PM EST) Monday-Friday:
- Phone: 800-875-2562 (toll free) or 703-964-5840
- E-mail: pcsupport@altum.com

**GENERAL QUESTIONS (ALL PROGRAMS)**

**Q:** Who is eligible to apply for these grants?

**A:** All principal investigators, who hold an academic faculty appointment of assistant, associate, or full professor or its equivalent, at non-profit organizations, or public or private institutions such as universities, colleges, hospitals, and laboratories in the United States and Canada, may apply, as long as the project fits the criteria outlined in the RFP. For-profit entities are not eligible to apply for LRF funds. Early career investigators are invited to apply for one of LRF’s Young Investigator Grant programs where appropriate. If you are unsure if your project is eligible for this grant, please contact researchgrants@lymphoma.org well in advance of the deadline.

**Q:** What are the citizenship requirements for applicants?

**A:** Eligible applicants must be a citizen of the United States or Canada or hold a visa to work in the United States or Canada. In addition, applicants must be able to commit to remaining at an American or Canadian institution for the duration of the project.

**Q:** Are American/Canadian citizens working at an institution in another country eligible?

**A:** No. Applicants to these programs must be based at an institution in the United States or Canada for the duration of the project.

**Q:** Are proposals with multiple Principal Investigators (PIs) acceptable?

**A:** Applications should be filed in the name of one person who will serve as the primary PI for administrative purposes (disbursing funds, filing reports, etc.). You may designate a “co-PI” in the Key Personnel section if appropriate to a collaborator’s role in the project.

**Q:** Is a Letter of Intent (LOI) required?

**A:** No LOI is required.

**Q:** How many letters of support are required?

**A:** Letters of support are not required, but applicants may submit up to three. Please note that all expected support
letters must be uploaded before applications are submitted. If the application includes a significant collaborative component from another institution or pharmaceutical partner, nonconfidential letters verifying support from these entities should be uploaded as part of the appendix.

Q: When is the proposal due?
A: The submission deadline is 5:00PM EST on Wednesday, September 6, 2017.

Q: Must a hard copy of the entire application be mailed?
A: No. Applicants are not required to mail a hard copy of any application component. Please note that the signature and waiver pages must be printed, signed by the appropriate institutional officials, and uploaded into the application as a PDF before submission.

Q: What font should I use?
A: Any legible font is acceptable, as long as the size is 11 points or bigger.

Q: Are there limits on the number of pages?
A: Where there are limits, they are indicated. For the research plan, references may be excluded from the 10 page limit. For letters of support or other appendix documents, the number of pages is optional but should not exceed 30 pages total.

Q: Is there a required format for the letters?
A: Letters of support are not required. If you are providing, the letters should be on institutional letterhead but the format is at the discretion of the writer.

Q: Why is proposalCENTRAL asking me to import my Other Research Support from my profile? Do I have to import this info or can I fill it in manually?
A: proposalCENTRAL allows applicants to store other research support in their individual profile and import it into an application as needed. Follow the directions on the application page to import funding from your profile to the application, or use the indicated buttons to open your profile to add new entries. For technical assistance with this section, contact proposalCENTRAL technical support at pcsupport@altum.com.

Q: Do I have to submit a budget?
A: Yes—you must complete section 10 of the application process, Budget Period Detail. Indicate how much you intend to spend on each category listed. Personnel costs may include fringe. Institutional overhead is permitted at up to 25% (smaller amounts are preferred). Please refer to each RFP for the total allowed budget for each grant; note the maximum budget allowed is inclusive of fringe and overhead.

Q: We have a subcontract in our proposal, how do I list that in the budget form?
A: List the direct costs of the subcontract as a line item under the “Other” section, and add any indirect costs to the total indirect costs line. Indirect costs for a subcontract are allowed, but the total indirect costs (both subcontract and PI Institution) should add up to no more than 25% of the total budget. LRF recommends including a budget justification document (in the Attachments section) for projects that incorporate a subcontract with a breakdown of the direct and indirect costs covered by the subcontract.

Q: What if I don’t have one or more of the required assurances (i.e. IRB, IACUC, biohazards) yet?
A: In the online Proposal Central application process, note the section called Organizational Assurances, select the appropriate response, i.e. if IRB approval has been requested but not yet received; select “pending” as the
response to that question. In that case there is no certificate to upload, so you simply skip that attachment (certificates are not required in order to submit your application). Please note however, that you must demonstrate receipt of the appropriate assurances in order to receive your award; if selected for funding, you will be asked to upload current certificates at that time.

Q: **Who conducts the grant review?**
A: Applications will be reviewed by members of LRF’s Scientific Advisory Board (SAB), which is comprised of some of the leaders in the field of lymphoma research, and, where applicable, members of LRF’s Adolescent/Young Adult Lymphoma Advisory Committee, which includes specialists in research for AYA lymphomas.

Q: **Will I have the opportunity to respond to feedback and re-submit my application?**
A: The LRF Scientific Advisory Board may elect to provide feedback to applicants discussed during the final round of review. This feedback will be for the improvement of future grant submissions only; responses and resubmissions during the current grant cycle are not permitted. The SAB’s decision is final.

Q: **When will I find out if I have been selected for an award?**
A: Applicants will be informed in writing in December 2017.

### AYA CORRELATIVE STUDIES GRANT QUESTIONS

Q: **What type of projects are appropriate for an AYA Correlative Studies Grant?**
A: Projects should be associated with an ongoing or recently completed clinical research project focused specifically on lymphoma and be focused on the priority areas as they affect adolescent and young adult patient populations; this can include studies where data collection will be completed in the time frame of the grant or projects which were designed with correlatives that are not covered by the trial’s funding source. Projects may focus on either biomarker/biology priority areas or clinical outcomes/survivorship/health services priority areas.

Q: **May projects focus on a specific subtype of lymphoma and not AYA lymphoma in general?**
A: Yes, studies within a specific subtype are eligible, as long as the project focuses on adolescent and young adult patient populations within that subtype.

Q: **How do the two priority areas work? May I apply with a separate project in both areas?**
A: LRF has designed the 2018 AYA Correlative Studies Grant to support correlative studies that address either biomarker/biology of lymphomas or clinical outcomes/health services research. You will be asked to select the most appropriate area for your project at the time of application. LRF hopes to fund at least one project in both areas. Please note that individuals designated as PIs or co-PIs on a project may only submit one application total this cycle.

Q: **Does the study need to include primary patient samples? Do all the samples need to be from AYA patients?**
A: Primary patient samples are not required, but the study should have direct clinical relevance/involvement or include primary lymphoma patient samples or data. Proposals should specify how many AYA patients or patient samples will be included in the study; if non-AYA samples will be incorporated, the proposal should specify their relevance to the study.
**MCL THERAPEUTIC STUDIES GRANT QUESTIONS**

Q: Are MCL Consortium members working at an institution outside the U.S. or Canada eligible?
A: No. Due to funding restrictions, applicants to this Initiative must be based at an institution in the United States or Canada for the duration of the project.

Q: What type of projects are appropriate for the MCL Therapeutic Studies Support Initiative?
A: Projects should be clinical/translational studies in mantle cell lymphoma, and relate to work in the clinical setting and/or involve primary MCL patient samples. Correlative studies are strongly encouraged, but smaller scale projects such as those performing specialized analyses on patient samples, or pilot or phase I or II clinical trials are also permitted. Please review the Research Objectives and Review Evaluative Factors sections of the RFP for details on types of projects and priority research areas.

Q: Does the study need to include primary patient samples? Do all the samples need to be from MCL patients?
A: The study should relate to work in the clinical setting and/or involve primary MCL patient samples. Research proposals should specify how many MCL patients or patient samples will be included in the study; if non-MCL samples will be incorporated, the proposal should specify their relevance to the study.